Lonza from Belgium, also known as Lonza Belgium NV, is a subsidiary of the Lonza Group, a leading global supplier to the pharmaceutical, healthcare, and life sciences industries. Lonza was originally established as a chemical company in 1897 in Basel, Switzerland. Over the years, it has evolved into a major player in the pharmaceutical and biotechnology markets.

Lonza's headquarters are located in Basel, Switzerland. The company offers a wide range of products and services to its global customers. Its main products include active pharmaceutical ingredients (APIs), cell therapy products, viral-based therapeutics, and biomanufacturing solutions.

Lonza also provides contract development and manufacturing services, including custom synthesis, drug product manufacturing, and process development. Lonza operates on a global scale, with multiple subsidiaries, joint ventures, and partnerships around the world. Some noteworthy subsidiaries include Lonza Pharma & Biotech, Lonza Specialty Ingredients, and Lonza Consumer Health.

The company has joint ventures with companies like Sanofi, Moderna, and BioMérieux. These partnerships enable Lonza to leverage its expertise and expand its global reach. In terms of market position, Lonza is one of the leading suppliers in the global pharmaceutical and healthcare industries.

The company has a strong presence in key markets, including North America, Europe, and Asia Pacific. Its global sales reached CHF 6. 1 billion (approximately USD 6.

5 billion) in 2020. Despite competition from other industry players, Lonza has managed to maintain a strong position due to its focus on innovation, quality, and customer service. Lonza has achieved several major milestones throughout its history.

In recent years, the company has made significant investments in expanding its manufacturing capabilities, particularly in the field of cell and gene therapy. This has allowed Lonza to position itself as a leading provider of services to the rapidly growing cell and gene therapy market. As of the latest update, Lonza continues to be a key player in the pharmaceutical and healthcare industries.

The company remains committed to driving innovation, expanding its offerings, and delivering value to its global customers